Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3500

Bromodomain-containing protein 3 (BRD3) or RING3-like protein (RING3L) is a protein that encodes the BRD3 gene. It plays a role in the regulation of transcription, probably by chromatin remodeling and interaction with transcription factors. It regulates transcription by promoting the binding of the transcription factor GATA1 to its targets.

The BRD3 – Drugs in Development research report provides a comprehensive overview on the therapeutics under development for BRD3, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for BRD3 and features dormant and discontinued projects.

Key Therapy Areas in the BRD3 Pipeline Drugs Market

The key therapy areas in the BRD3 pipeline drugs market are Oncology, Dermatology and Immunology.

BRD3 Pipeline Drugs Market, by Targets

BRD3 Pipeline Drugs Market, by Targets

For more target insights, download a free report sample

Key MoA in the BRD3 Pipeline Drugs Market

The key mechanism of action in the BRD3 pipeline drugs market is Bromodomain Containing Protein 3 Inhibitor.

BRD3 pipeline Drugs Market Segmentation by RoA

The key routes of administration in the BRD3 pipeline drugs market are Oral and Topical.

BRD3 pipeline Drugs Market Analysis, by RoA

BRD3 pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the BRD3 pipeline Drugs Market

The key molecule type in the BRD3 pipeline drugs market is Small Molecule.

Major Companies in the BRD3 pipeline Drugs Market

The major companies in the BRD3 pipeline drugs market are Zenith Epigenetics Ltd, VYNE Therapeutics Inc, Ningbo Wenda Pharmaceutical Technology Co Ltd, Constellation Pharmaceuticals Inc, Bristol-Myers Squibb Co, Amgen Inc, and AbbVie Inc.

BRD3 pipeline Drugs Market, by Major Companies

BRD3 pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

BRD3 Pipeline Drugs Market Overview

Key Therapy Areas Oncology, Dermatology and Immunology
Key Mechanisms of action Bromodomain Containing Protein 3 Inhibitor
Key Routes of Administration Oral and Topical
Key molecule types Small Molecule
Major companies Zenith Epigenetics Ltd, VYNE Therapeutics Inc, Ningbo Wenda Pharmaceutical Technology Co Ltd, Constellation Pharmaceuticals Inc, Bristol-Myers Squibb Co, Amgen Inc, and AbbVie Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of BRD3
  • The pipeline guide reviews pipeline therapeutics for BRD3 by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in BRD3 therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates BRD3 therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for BRD3

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for BRD3
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding BRD3 pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

AbbVie Inc
Amgen Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Constellation Pharmaceuticals Inc
Ningbo Wenda Pharmaceutical Technology Co Ltd
Roivant Sciences Ltd
VYNE Therapeutics Inc
Zenith Epigenetics Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) – Overview

Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) – Companies Involved in Therapeutics Development

AbbVie Inc

Amgen Inc

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Co

Constellation Pharmaceuticals Inc

Ningbo Wenda Pharmaceutical Technology Co Ltd

Roivant Sciences Ltd

VYNE Therapeutics Inc

Zenith Epigenetics Ltd

Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) – Drug Profiles

ABBV-744 – Drug Profile

Product Description

Mechanism Of Action

History of Events

BI-894999 – Drug Profile

Product Description

Mechanism Of Action

History of Events

CC-95775 – Drug Profile

Product Description

Mechanism Of Action

History of Events

NHWD-870 – Drug Profile

Product Description

Mechanism Of Action

History of Events

NUE-19796 – Drug Profile

Product Description

Mechanism Of Action

History of Events

pelabresib – Drug Profile

Product Description

Mechanism Of Action

History of Events

QCA-570 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Target BET 3 and MDM2 for Metastatic Castration Resistant Prostate Cancer – Drug Profile

Product Description

Mechanism Of Action

History of Events

VYN-201 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ZEN-3694 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) – Dormant Products

Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) – Discontinued Products

Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) – Product Development Milestones

Featured News & Press Releases

Mar 07, 2022: VYNE reports positive preclinical data for lead BET Inhibitor, VYN201, in human skin model of vitiligo

Feb 22, 2022: Zenith Epigenetics announces dosing of first cancer patient with a combination of ZEN-3694 + Bristol Myers Squibb’s immune checkpoint inhibitor OPDIVO

Dec 12, 2021: MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis

Nov 04, 2021: MorphoSys to present MANIFEST data from expanded hematology-oncology portfolio at the 2021 American Society of Hematology (ASH) Annual Meeting

Nov 04, 2021: Lead BET inhibitor, VYN201, demonstrates improvement in reducing fibrotic tissue mass and overall skin repair outcomes in preclinical study

Oct 26, 2021: Lead BET inhibitor, VYN201, significantly reduces expression of several key pro-inflammatory cytokines in preclinical studies

Sep 21, 2021: Zenith Epigenetics and Newsoara announce initiation of a randomized phase 2b metastatic castration-resistant prostate cancer (mCRPC) study

Aug 17, 2021: Zenith Epigenetics announces a publication in the journal of Cancer Gene Therapy with compelling data for the treatment of ER-positive breast cancer patients

Jun 24, 2021: Zenith Epigenetics announces a publication highlighting the role of ZEN-3694 in overcoming resistance to therapies in metastatic castration-resistant prostate cancer

Jun 11, 2021: Constellation Pharmaceuticals provides an update from the ongoing MANIFEST study of Pelabresib

Jun 11, 2021: Constellation Pharmaceuticals provides an update from the Ongoing MANIFEST study of Pelabresib

Mar 15, 2021: Zenith Epigenetics announces dosing of first mCRPC patient with a combination of ZEN-3694 + Merck’s immune check point inhibitor KEYTRUDA

Jan 07, 2021: Constellation Pharmaceuticals appoints Brendan Delaney as Chief Commercial Officer

Dec 06, 2020: Constellation Pharmaceuticals provides update of MANIFEST study for CPI-0610 at ASH Meeting

Nov 23, 2020: Constellation Pharmaceuticals to host analyst / investor event to discuss update of MANIFEST clinical trial for CPI-0610 presented at ASH Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Indications, 2022 (Contd..1)

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by AbbVie Inc, 2022

Pipeline by Amgen Inc, 2022

Pipeline by Boehringer Ingelheim International GmbH, 2022

Pipeline by Bristol-Myers Squibb Co, 2022

Pipeline by Constellation Pharmaceuticals Inc, 2022

Pipeline by Ningbo Wenda Pharmaceutical Technology Co Ltd, 2022

Pipeline by Roivant Sciences Ltd, 2022

Pipeline by VYNE Therapeutics Inc, 2022

Pipeline by Zenith Epigenetics Ltd, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Frequently asked questions

Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$3,500

Can be used by individual purchaser only

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.